Jeito

Jeito company information, Employees & Contact Information

Explore related pages

Related company profiles:

Jeito is a next-generation fund with a patient benefit driven approach, that focuses both on financing ground-breaking medical innovation and promoting positive societal impact. We empower and support entrepreneurs through our expert, integrated, multi-talented team. Jeito Capital is based in Paris with a presence in Europe and the United States. Follow us to get our latest news & job offers.

Company Details

Employees
40
Founded
-
Address
2, Rue Pillet Will, Paris,île-De-France 75009,france
Industry
Venture Capital And Private Equity Principals
NAICS
Miscellaneous Intermediation
Website
jeito.life
HQ
Paris, Île-de-France
Looking for a particular Jeito employee's phone or email?

Jeito Questions

News

Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs - GlobeNewswire

Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs GlobeNewswire

Affinity Asset Advisors/TPG Life Sciences Innovations Joins $213M Series D For Odyssey Therapeutics - citybiz

Affinity Asset Advisors/TPG Life Sciences Innovations Joins $213M Series D For Odyssey Therapeutics citybiz

Jeito Capital promotes Ksenija Pavletic to General Partner - The Manila Times

Jeito Capital promotes Ksenija Pavletic to General Partner The Manila Times

Jeito Capital Strengthens Leadership for Next Chapter of - GlobeNewswire

Jeito Capital Strengthens Leadership for Next Chapter of GlobeNewswire

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors - Business Wire

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors Business Wire

Women-Led Jeito Capital Closes on $630 Million Life Sciences Investment Fund - BioSpace

Women-Led Jeito Capital Closes on $630 Million Life Sciences Investment Fund BioSpace

Jeito Capital Closes Its Latest Fund, Jeito I, at $630m - Private Equity Insights

Jeito Capital Closes Its Latest Fund, Jeito I, at $630m Private Equity Insights

Jeito Capital announces significant participation in $187 - GlobeNewswire

Jeito Capital announces significant participation in $187 GlobeNewswire

French PE fund Jeito Capital invests in global biopharma growth with Aviceda and XyloCor Therapeutics - EU-Startups

French PE fund Jeito Capital invests in global biopharma growth with Aviceda and XyloCor Therapeutics EU-Startups

Swiss biotech CDR Life uses $76M series A funding round to ready T-cell engagers for clinic - Fierce Biotech

Swiss biotech CDR Life uses $76M series A funding round to ready T-cell engagers for clinic Fierce Biotech

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing - FinancialContent

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing FinancialContent

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders - Business Wire

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders Business Wire

Jeito Capital leads $67.5 million (€64.4 million[1]) Series - GlobeNewswire

Jeito Capital leads $67.5 million (€64.4 million[1]) Series GlobeNewswire

XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease - Business Wire

XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease Business Wire

Jeito Capital Leads a USD 65 million Financing in ReproNovo - GlobeNewswire

Jeito Capital Leads a USD 65 million Financing in ReproNovo GlobeNewswire

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 - GlobeNewswire

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 GlobeNewswire

EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies - Business Wire

EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies Business Wire

Top Jeito Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant